摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-(2-(2-(4-(5-(4-acrylamido-6-aminopyrimidin-2-ylthio)-4,6-dimethoxypyrimidin-2-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl acrylate | 1268273-45-5

中文名称
——
中文别名
——
英文名称
2-(2-(2-(2-(4-(5-(4-acrylamido-6-aminopyrimidin-2-ylthio)-4,6-dimethoxypyrimidin-2-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl acrylate
英文别名
2-[2-[2-[2-[4-[5-[4-Amino-6-(prop-2-enoylamino)pyrimidin-2-yl]sulfanyl-4,6-dimethoxypyrimidin-2-yl]piperazin-1-yl]ethoxy]ethoxy]ethoxy]ethyl prop-2-enoate
2-(2-(2-(2-(4-(5-(4-acrylamido-6-aminopyrimidin-2-ylthio)-4,6-dimethoxypyrimidin-2-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl acrylate化学式
CAS
1268273-45-5
化学式
C28H40N8O8S
mdl
——
分子量
648.74
InChiKey
ZFQGQZZITPOSSM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    45
  • 可旋转键数:
    21
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    211
  • 氢给体数:
    2
  • 氢受体数:
    16

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(2-(2-(2-(4-(5-(4-acrylamido-6-aminopyrimidin-2-ylthio)-4,6-dimethoxypyrimidin-2-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl acrylate 在 sodium hydroxide 作用下, 以 四氢呋喃 为溶剂, 反应 3.0h, 以75%的产率得到N-(6-amino-2-(2-(4-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)-4,6-dimethoxypyrimidin-5-ylthio)pyrimidin-4-yl)acrylamide
    参考文献:
    名称:
    Heat Shock Protein 70 Inhibitors. 1. 2,5′-Thiodipyrimidine and 5-(Phenylthio)pyrimidine Acrylamides as Irreversible Binders to an Allosteric Site on Heat Shock Protein 70
    摘要:
    Heat shock protein 70 (Hsp70) is an important emerging. cancer. target whose inhibition may affect multiple cancer-associated signaling pathways and, moreover, result in significant cancer cell apoptosis. Despite considerable interest from both academia and pharmaceutical companies in the discovery and development of druglike Hsp70 inhibitors, little success has been reported so far. Here we describe structure activity relationship studies in the first rationally designed Hsp70 inhibitor class that binds to a novel allosteric pocket located in the N-terminal domain of the protein. These 2,5'-thiodipyrimidine and 5-(phenylthio)-pyrimidine acrylamides take advantage of an active cysteine embedded in the allosteric pocket to act as covalent protein modifiers upon binding. The study identifies derivatives 17a and 20a, which selectively bind to Hsp70 in cancer cells. Addition of high nanomolar to low micromolar concentrations of these inhibitors to cancer cells leads to a reduction in the steady-state levels of Hsp70-sheltered oncoproteins, an effect associated with inhibition of cancer cell growth and apoptosis. In summary, the described scaffolds represent a viable starting point for the development of druglike Hsp70 inhibitors as novel anticancer therapeutics.
    DOI:
    10.1021/jm401551n
  • 作为产物:
    参考文献:
    名称:
    [EN] HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME
    [FR] COMPOSÉS DE LIAISON À UNE PROTÉINE DE CHOC THERMIQUE, COMPOSITIONS ET PROCÉDÉS POUR LES FABRIQUER ET LES UTILISER
    摘要:
    公开号:
    WO2011022440A9
点击查看最新优质反应信息

文献信息

  • HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME
    申请人:Chiosis Gabriela
    公开号:US20120252818A1
    公开(公告)日:2012-10-04
    The present subject matter relates to a compound represented by the general formula (I) or (I′) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).
    本主题涉及一种由通式(I)或(I′)表示的化合物或其药学上可接受的盐;包含至少一种这些化合物的制药组合物;制备至少一种这些化合物的方法;使用至少一种这些化合物治疗和/或预防各种癌症和/或增殖障碍的方法;使用至少一种这些化合物监测抗癌治疗对各种癌症的有效性的方法。在一种实施方式中,本主题涉及与热休克蛋白70(Hsp70)具有特异性结合的化合物。在另一种实施方式中,本主题涉及与具有特异性抑制热休克蛋白70(Hsp70)和热休克同源蛋白70(Hsc70)的化合物的结合。
  • Heat shock protein binding compounds, compositions, and methods for making and using same
    申请人:Memorial Sloan-Kettering Cancer Center
    公开号:US10052325B2
    公开(公告)日:2018-08-21
    The present subject matter relates to a compound represented by the general formula (I) or (I′) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).
    本主题涉及通式(I)或(I′)代表的化合物或其药理学上可接受的盐;含有至少一种这些化合物的药物组合物;制造至少一种这些化合物的方法;使用至少一种这些化合物治疗和/或预防各种癌症和/或增殖障碍的方法;使用至少一种这些化合物监测抗癌疗法对各种癌症的疗效的方法。在一个实施方案中,该主题涉及与热休克蛋白 70(Hsp70)具有一定特异性结合的化合物。在另一个实施方案中,本发明涉及的化合物具有一定程度的特异性,可同时抑制热休克蛋白70(Hsp70)和热休克同源蛋白70(Hsc70)。
  • [EN] HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME<br/>[FR] COMPOSÉS DE LIAISON À UNE PROTÉINE DE CHOC THERMIQUE, COMPOSITIONS ET PROCÉDÉS POUR LES FABRIQUER ET LES UTILISER
    申请人:MEMORIAL SLOAN KETTERING CANCER CENTER
    公开号:WO2011022440A9
    公开(公告)日:2016-11-10
  • 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders
    申请人:Memorial Sloan-Kettering Cancer Center
    公开号:EP2467142B1
    公开(公告)日:2016-09-21
  • EP3205647A2
    申请人:——
    公开号:EP3205647A2
    公开(公告)日:2017-08-16
查看更多